• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝硬化患者药物处置的决定因素。

Determinants of drug disposition in patients with cirrhosis.

作者信息

Huet P M, Villeneuve J P

出版信息

Hepatology. 1983 Nov-Dec;3(6):913-8. doi: 10.1002/hep.1840030604.

DOI:10.1002/hep.1840030604
PMID:6629320
Abstract

The effects of alterations of the hepatic blood flow, the intrinsic clearance, and the anatomy of the portal circulation on drug disposition were investigated in 53 cirrhotic patients with portal hypertension using indocyanine green (ICG) and lidocaine as model drugs. ICG disposition was studied by sampling from an artery and one hepatic vein following i.v. injection, with determination of systemic and intrinsic clearances and hepatic blood flow. Lidocaine disposition was studied following i.v. and oral administration from peripheral vein disappearance curves, with determination of systemic and intrinsic clearances and systemic availability. The shunted fraction of intestinal blood flow (f) was measured from the combined ICG and lidocaine disposition studies. In the 53 patients, systemic clearances of ICG and lidocaine varied widely and were significantly correlated with each other (r = 0.725, p less than 0.001). The systemic clearances of both ICG and lidocaine were not related to hepatic blood flow but were significantly correlated to their respective intrinsic clearances (for ICG: r = 0.948, p less than 0.001; for lidocaine: r = 0.873, p less than 0.001). Lidocaine systemic availability was also found to vary widely from 0.2 to 1.0. In 28 patients, f was less than 0.1 indicating minimal extrahepatic shunting and in these patients, lidocaine systemic availability was related to its intrinsic clearance (r = -0.717, p less than 0.001); in the 25 other patients with significant extrahepatic shunting (f greater than 0.1), the extent of lidocaine systemic availability was related to both intrinsic clearance (r = -0.819, p less than 0.001) and extrahepatic shunting (r = 0.913, p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

以53例门静脉高压症肝硬化患者为研究对象,以吲哚菁绿(ICG)和利多卡因为模型药物,研究肝血流量、内在清除率及门静脉循环解剖结构改变对药物处置的影响。静脉注射ICG后,通过采集动脉血和一条肝静脉血样,测定全身清除率、内在清除率和肝血流量,以此研究ICG的处置情况。通过外周静脉血消失曲线,测定静脉注射和口服利多卡因后的全身清除率、内在清除率和全身生物利用度,研究利多卡因的处置情况。综合ICG和利多卡因处置研究结果,测量肠道血流分流分数(f)。在这53例患者中,ICG和利多卡因的全身清除率差异很大,且两者显著相关(r = 0.725,p < 0.001)。ICG和利多卡因的全身清除率均与肝血流量无关,但与各自的内在清除率显著相关(ICG:r = 0.948,p < 0.001;利多卡因:r = 0.873,p < 0.001)。还发现利多卡因的全身生物利用度差异也很大,在0.2至1.0之间。在28例患者中,f < 0.1,表明肝外分流极少,在这些患者中,利多卡因的全身生物利用度与其内在清除率相关(r = -0.717,p < 0.001);在另外25例有明显肝外分流(f > 0.1)的患者中,利多卡因全身生物利用度的程度与内在清除率(r = -0.819,p < 0.001)和肝外分流(r = 0.913,p < 0.001)均相关。(摘要截选至250字)

相似文献

1
Determinants of drug disposition in patients with cirrhosis.肝硬化患者药物处置的决定因素。
Hepatology. 1983 Nov-Dec;3(6):913-8. doi: 10.1002/hep.1840030604.
2
Effect of portacaval shunt on drug disposition in patients with cirrhosis.门腔分流术对肝硬化患者药物处置的影响。
Gastroenterology. 1986 Jul;91(1):163-7. doi: 10.1016/0016-5085(86)90453-1.
3
Effects of smoking and chronic hepatitis B on lidocaine and indocyanine green kinetics.吸烟和慢性乙型肝炎对利多卡因和吲哚菁绿动力学的影响。
Clin Pharmacol Ther. 1980 Aug;28(2):208-15. doi: 10.1038/clpt.1980.152.
4
Reliability of the estimation of total hepatic blood flow by Doppler ultrasound in patients with cirrhotic portal hypertension.多普勒超声估计肝硬化门脉高压患者总肝血流量的可靠性。
J Hepatol. 2013 Oct;59(4):717-22. doi: 10.1016/j.jhep.2013.04.037. Epub 2013 May 10.
5
Prognostic value of indocyanine green and lidocaine kinetics for survival and chronic hepatic encephalopathy in cirrhotic patients following elective end-to-side portacaval shunt.肝硬化患者择期端侧门腔分流术后吲哚菁绿和利多卡因动力学对生存及慢性肝性脑病的预后价值
Hepatology. 1988 Nov-Dec;8(6):1506-10. doi: 10.1002/hep.1840080607.
6
Disposition of a flow-limited drug (lidocaine) and a metabolic capacity-limited drug (theophylline) in liver cirrhosis.肝硬化患者中流量限制型药物(利多卡因)和代谢能力限制型药物(茶碱)的处置情况。
Clin Pharmacol Ther. 1988 Dec;44(6):642-9. doi: 10.1038/clpt.1988.206.
7
Indocyanine green retention test in cirrhosis and portal hypertension: Accuracy and relation to severity of disease.肝硬化和门静脉高压症中吲哚菁绿保留试验:准确性及其与疾病严重程度的关系。
J Gastroenterol Hepatol. 2019 Jun;34(6):1093-1099. doi: 10.1111/jgh.14470. Epub 2018 Oct 4.
8
Combined hepatic vein, umbilicoportal vein, and superior mesenteric artery catheterization in portal hypertension: estimation of the portal fraction of total hepatic blood flow in cirrhotic patients.联合肝静脉、脐门静脉和肠系膜上动脉插管用于门静脉高压症:肝硬化患者肝总血流量门静脉部分的评估
Yale J Biol Med. 1975 Mar;48(1):55-66.
9
Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: lidocaine and indocyanine green.病毒性肝炎对两种肝清除率高的化合物(利多卡因和吲哚菁绿)处置的影响。
Clin Pharmacol Ther. 1976 Sep;20(3):290-9. doi: 10.1002/cpt1976203290.
10
Determination of hepatic clearance by derivations of the indocyanine green retention test in cirrhosis.通过吲哚菁绿潴留试验推导法测定肝硬化患者的肝清除率。
J Gastroenterol Hepatol. 2022 Apr;37(4):692-699. doi: 10.1111/jgh.15778. Epub 2022 Feb 2.

引用本文的文献

1
Optimizing Lidocaine Dosing in Hepatectomy Patients: A Population Pharmacokinetic Study of Active Metabolites.优化肝切除患者的利多卡因给药剂量:活性代谢物的群体药代动力学研究
Drug Des Devel Ther. 2025 Jul 22;19:6255-6268. doi: 10.2147/DDDT.S485389. eCollection 2025.
2
Population Pharmacokinetics of Intravenous Lidocaine in Adults: A Systematic Review.成人静脉利多卡因的群体药代动力学:系统评价。
Clin Pharmacokinet. 2024 May;63(5):623-643. doi: 10.1007/s40262-024-01373-4. Epub 2024 May 4.
3
Physiologically Based Modeling of the Effect of Physiological and Anthropometric Variability on Indocyanine Green Based Liver Function Tests.
基于生理和人体测量变异性对基于吲哚菁绿的肝功能测试影响的生理模型。
Front Physiol. 2021 Nov 22;12:757293. doi: 10.3389/fphys.2021.757293. eCollection 2021.
4
A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis.系统评价他汀类药物在肝硬化中的药代动力学、心血管结局和安全性特征。
BMC Gastroenterol. 2021 Mar 16;21(1):120. doi: 10.1186/s12876-021-01704-w.
5
Systemic hemodynamics in advanced cirrhosis: Concerns during perioperative period of liver transplantation.晚期肝硬化的全身血流动力学:肝移植围手术期的关注点
World J Hepatol. 2016 Sep 8;8(25):1047-60. doi: 10.4254/wjh.v8.i25.1047.
6
Pharmacokinetic drug interactions in liver disease: An update.肝病中的药代动力学药物相互作用:最新进展。
World J Gastroenterol. 2016 Jan 21;22(3):1260-78. doi: 10.3748/wjg.v22.i3.1260.
7
Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient.索拉非尼的代谢在肝细胞癌患者的肝肿瘤组织中发生显著改变。
PLoS One. 2014 May 5;9(5):e96664. doi: 10.1371/journal.pone.0096664. eCollection 2014.
8
Psychiatric treatment considerations with direct acting antivirals in hepatitis C.丙型肝炎直接作用抗病毒药物治疗的精神科考虑因素。
BMC Gastroenterol. 2013 May 14;13:86. doi: 10.1186/1471-230X-13-86.
9
Antiarrhythmics: elimination and dosage considerations in hepatic impairment.抗心律失常药:肝功能损害时的消除及剂量考量
Clin Pharmacokinet. 2007;46(12):985-96. doi: 10.2165/00003088-200746120-00002.
10
Stability of cirrhotic systemic hemodynamics ensures sufficient splanchnic blood flow after living-donor liver transplantation in adult recipients with liver cirrhosis.肝硬化患者全身血流动力学的稳定性确保了成人肝硬化活体肝移植受者术后有足够的内脏血流。
World J Gastroenterol. 2007 Nov 28;13(44):5918-25. doi: 10.3748/wjg.v13.i44.5918.